A recent study highlights the effectiveness of treatments provided to patients of severe combined immunodeficiency (SCID). The study reveals a relationship between the genotype of the patients SCID ...

For decades, scientists have been trying to find ways to cure disorders that can be traced back to an error in one gene. One of the first diseases that researchers ...

June 28, 2002 -- Gene therapy and nonmyeloablative conditioning effectively treated two "bubble babies" suffering from the adenosine deaminase deficiency form of severe combined immunodeficiency ...

CD3δ deficiency is a rare form of SCID (T−B+NK+). 8 Although CD3-deficient patients who received HSCT with or without chemotherapy conditioning have been reported, 9 it is not clear whether sufficient ...

NEW ORLEANS -- A next generation genetic therapy appeared to restore the immune system of patients with "bubble boy disease," but without leading to leukemia as a side effect, researchers reported ...

GAITHERSBURG, Md.--(BUSINESS WIRE)--Leadiant Biosciences, Inc. today announced that the Food and Drug Administration (FDA) has granted approval to Revcovi™ (elapegademase-lvlr) injection in the U.S.

Severe combined immunodeficiency (SCID) occurs in just one out of every 50,000 to 100,000 births in the United States, yet it is the most serious primary immunodeficiency disorder. A new study ...

A gene therapy for a rare type of severe combined immunodeficiency (SCID) was safe and sufficiently restored T-cell immunity in an early trial, results from a phase I/II study showed. At a single ...

SCID is a fatal syndrome caused by mutations in at least 13 different genes. It is characterized by the absence of T cells. Immune reconstitution can be achieved through nonablative related donor BMT.

Leadiant Biosciences, Inc. today announced that the Food and Drug Administration (FDA) has granted approval to Revcovi ™ (elapegademase-lvlr) injection in the U.S. Revcovi is a new enzyme replacement ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, today announced clinical data from its ongoing multicenter ...